The therapeutic potency of targeting these cytokines have been demonstrated in actual clinical trials with anti-TNF-α antibodies [52], as well as in in vivo studies where colitis showed attenuation upon DSS stimulation in IFN-γ−/− mice [58]. This evidence concerns the gene IFNG and colitis.